Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of NMK89, a 89Zr-labeled hNd2 radiotracer, evaluating safety, tolerability, pharmacokinetics, radiation dosimetry, and PET imaging properties in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• NMK89 (89Zr-labeled hNd2 radiotracer)

Snippet

Sponsor: Nihon Medi-Physics Co., Ltd. | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED